Bloomin’ Brands Q1 Earnings Exceed Expectations

Bloomin’ Brands Inc (NASDAQ:BLMN) reported first-quarter FY22 sales growth of 15.5%, to $1.14 billion, beating the consensus of $1.13 billion.…
  • Bloomin’ Brands Inc (NASDAQ:BLMN) reported first-quarter FY22 sales growth of 15.5%, to $1.14 billion, beating the consensus of $1.13 billion.
  • Combined U.S. comparable restaurant sales grew 14.0% during the quarter, with 9.2% growth in Outback Steakhouse and 11.5% in Carrabba’s Italian Grill.
  • Restaurant sales grew 14.7% Y/Y to $1.1 billion, while Franchise and other revenues shot up 111.4% to $16.9 million.
  • U.S. segment revenue rose 14.5% Y/Y to $1.04 billion, and the International segment increased 26% Y/Y to $104 million.
  • Total cost and expenses for the quarter increased 15.3% Y/Y to $1 billion.
  • Restaurant-level operating margin contracted by 170 basis points to 17.1%.
  • Operating margin was 9.4%, and the operating income was $107.3 million.
  • The company held $97.7 million in cash and equivalents as of March 27, 2022. The company had a net debt of $722 million.
  • Adjusted EPS of $0.80 beat the analyst consensus of $0.74.
  • Outlook: Bloomin’ Brands raised its FY22 sales outlook to $4.35 billion – $4.4 billion from $4.3 billion – $4.35 billion, versus the consensus of $4.34 billion.
  • It raised the FY22 Adjusted EPS outlook to $2.45 – $2.55 from $2.35 – $2.45 versus the consensus of $2.39.
  • Bloomin’ sees Q2 sales of $1.1 billion – $1.13 billion versus the consensus of $1.08 billion.
  • It expects Q2 adjusted EPS of $0.60 – $0.65, against the consensus of $0.60.
  • Price Action: BLMN shares are trading lower by 0.75% at $21.84 on the last check Friday.
Total
0
Shares
Related Posts
Read More

2 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

ATLO

Read More

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the

KYMR